Half-year report · Q2
7459.TEDINET S100UQW8
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.82T | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥3.56T | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.78T | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥27.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥20.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥35.1bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥64.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥29.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥39.8bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥32.8bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥21.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥41.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥17.2bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥27.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥22.5bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥1.88T | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥1.80T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.82T | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.12T | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥1.06T | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥757.7bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥736.6bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥714.6bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥251.1bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥230.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥249.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥228.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥207.0bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥193.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥41.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥61.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥31.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥10.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥14.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥25.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥12.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥103.94 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.83 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥80.48 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.4% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.1% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥161m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥58.6bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥58.6bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥600.4bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥600.2bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥201m |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.17T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.17T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.83T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.82T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥27.0bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥1.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥1.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥37m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥56.8bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥56.8bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥583.4bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥583.3bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥146m |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.14T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.14T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥5.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.78T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.78T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥20.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 513
| Item | Context | Value | Unit |
|---|---|---|---|
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | -4000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 7677000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 20931000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 193561000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 228084000000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | Prior1YTDDuration | 5744000000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | CurrentYTDDuration | － | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 206983000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 249016000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1138946000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 583273000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 56769000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1778989000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 1778989000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1055000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 146000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1203000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -1203000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1140001000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 583420000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 56771000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1780193000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -1203000000 | JPY |
| Net sales | Prior1YTDDuration | 1778989000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 5362000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 13769000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 1537000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 20668000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -37000000 | JPY |
| Operating income | Prior1YTDDuration | 20631000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1165840000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 600226000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 58606000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1824672000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 1824672000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1795000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 201000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1998000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -1998000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1167635000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 600427000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 58607000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1826671000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -1998000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |